Cathie Wood’s ARK sells BWX Technologies stock, buys GeneDx

ARK Investment Management, the prominent investment firm led by CEO Cathie Wood, executed significant portfolio adjustments on Tuesday, March 18, 2025, by selling shares in defense contractor BWX Technologies and purchasing shares in genetic testing company GeneDx. The trades were executed through the firm's flagship ARK Innovation ETF (ARKK), reflecting a strategic reallocation of capital away from the defense sector and toward the disruptive innovation in genomics that aligns with the firm's core investment thesis. The sale of BWX Technologies stock, a company specializing in nuclear components and technical services for the U.S. Department of Energy and Department of Defense, represents a notable shift. While defense stocks have seen strong performance in recent years, ARK's philosophy centers on identifying and investing in companies poised to benefit from technological breakthroughs that will define the future. The move to divest from BWX suggests a calculated decision to reduce exposure to traditional government contracting in favor of higher-growth potential in other sectors. Conversely, the purchase of GeneDx Holdings Corp. stock reinforces ARK's long-standing conviction in the genomics revolution. GeneDx, a leader in genomic testing and analysis, operates squarely within ARK's thematic focus on 'Genomic Revolution,' one of its five major innovation platforms. The investment signals continued confidence in the company's ability to leverage decreasing DNA sequencing costs and expanding datasets to transform personalized medicine and disease diagnosis. This trade exemplifies ARK's active management style, where it regularly rebalances its ETFs to concentrate assets in what it believes are the most compelling innovation-driven opportunities, even if it means exiting profitable positions in more conventional industries.